Stock Ratings / Health Care / DYAI / forecast

ABOS (33) SCLX (40) PLUR (34) JSPR (36) ⌘ Pro Terminal →

Dyadic International Inc. (DYAI) 12-Month Stock Forecast & Price Target Cone

$0.38 +5.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.38

Dyadic International Inc. (DYAI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $15.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on DYAI Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.38 (+5.32% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYAI ranks #775 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does DYAI compare to ABOS and SCLX in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for DYAI?

▼

Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.38 (+0.77%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-13.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYAI)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY DYAI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)

FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.43-9.3% Next Q

Q2 (-2Q)

Grade E$0.39+0% Next Q

Q3 (-1Q)

Grade E$0.39-2.6% Next Q

Current

Grade E$0.38-9.4% Hist 90D α

Trajectory: E (39) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DYAI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DYAI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.40) forces dealer call-delta covering toward $1.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DYAI• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DYAI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your DYAI Position Size: $10,000

Shares at $0.38: 26315.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $0.26

$6,842

$-3,158 (-31.6%)

12M Consensus BaseTarget $0.33

$8,684

$-1,316 (-13.2%)

12M Bull Case BreakoutTarget $1.68

$44,211

+$34,211 (+342.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$0	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$0	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYAI)

✓Walkthrough of DYAI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DYAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.33%▲ RESISTANCE BREAKOUT

2026-11-03O $0.36H $0.38L $0.36C $0.38VOL 113.5K

RES: $0.37SUP: $0.20SMA50: $0.45SMA200: $0.76

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DYAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DYAI Butterfly Map → + Track DYAI →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DYAI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DYAI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DYAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYAI)

Health Care Rank #775 of 1016 ⚔️ ABOS vs DYAI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DYAI vs. ABOS, SCLX, PLUR, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyadic International Inc. (DYAI) ranks #775 by composite RQD confidence (31/100, grade E) and #854 by equity capitalization ($15.2M). Within this direct 5-issuer industry benchmark cohort, DYAI leads on earnings valuation at N/A trailing P/E, while DYAI leads on capital efficiency and profitability with -35.0% ROIC and 24.9% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with DYAI at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DYAI ACTIVE Dyadic International Inc.	E	31/100	—	24.9%	-35.0%	+5.32%	$15.2M	Benchmark Subject
ABOS Acumen Pharmaceuticals Inc.	E	33/100	—	—	-35.0%	-90.82%	$15.2M	/abos-vs-dyai →
SCLX Scilex Holding Company	D-	40/100	—	96.0%	-35.0%	-10.19%	$15.7M	/sclx-vs-dyai →
PLUR Pluri Inc.	E	34/100	—	49.0%	-35.0%	+3.33%	$16.7M	/plur-vs-dyai →
JSPR Jasper Therapeutics Inc.	D-	36/100	—	—	-35.0%	-2.22%	$17.3M	/jspr-vs-dyai →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213809

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyadic International Inc. (DYAI) reported GAAP revenue of $3.1M (-11.6% vs. FY2024 revenue of $3.5M , and +6.6% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$5.7M, and free cash flow of -$5.7M (-43.5% YoY). On the balance sheet, DYAI closed FY2025 with $9.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.1M	-$7.4M	-$5.7M	-$5.7M	$9.9M	—
FY2024 (FY)	2024-12-31	$3.5M	-$5.8M	-$4.0M	-$4.0M	$9.9M	—
FY2023 (FY)	2023-12-31	$2.9M	-$6.8M	-$6.7M	-$6.7M	—	—

3. DYAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does DYAI compare to ABOS and SCLX in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for DYAI?

Where is DYAI trading relative to its 50-day, 200-day, and 52-week technical levels?

DYAI last traded at $0.38 (+5.32% on volume of 113,466 shares), positioning the stock -15.56% below its 50-day simple moving average ($0.45) and -50.00% below its 200-day simple moving average ($0.76). Across its 52-week range of $0.34 to $1.60, DYAI sits at the 3.2% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).

DYAI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DYAI's 12-month stock price target?

Dyadic International Inc. (DYAI) carries a 12-month consensus base price target of $0.33 (-13.2% from $0.38), with a bull-case target of $1.68 and a bear-case floor of $0.26.

Is DYAI stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates DYAI E (Strong Sell — SELL) with an RQD Confidence score of 31/100.

Direct Sub-Reports: DYAI RQD Cockpit DYAI 12M Forecast DYAI Earnings & Move DYAI Dividends & DRIP DYAI Insiders & 13F DYAI Whale Options DYAI Profit Sankey DYAI News & Why

ROARABLE RATING BRIEF • RQD 31/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

DYAI — Dyadic International Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:50:45Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, DYAI scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 6 of 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating cash returns relative to capital. The whale 13F flow pillar scores 10 of 20 for institutional accumulation and options positioning, the strongest of the five but still below midpoint. Insider conviction scores 3 of 20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest signal in the rating. Macro regime fit scores 7 of 20 (Beta 1.0; sector sensitivity). The forensic balance sheet pillar scores 5 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), signaling elevated distress and weak accounting-quality markers. For a prospective investor, the upside case rests mainly on institutional positioning rather than operating performance, while valuation tradeoffs are dominated by negative margins and the absence of free-cash-flow yield. The rating itself is an analytical classification and not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$3.1M	$-7.2M	$-7.4M	N/A	$-5.7M	$4.6M	N/A
FY 2024	$3.5M	$-5.9M	$-5.8M	N/A	$-4.0M	$6.5M	N/A
FY 2023	$2.9M	$-8.2M	$-6.8M	N/A	$-6.7M	N/A	N/A

Per the SEC financials and market data, operating margin and net margin are both -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash declined from $6.5M in FY 2024 to $4.6M in FY 2025 alongside continued negative free cash flow.

Recent Catalysts & News Wire Analysis

Per the recent news data, DYAI-related items include a headline announcing that Dyadic will report Q3 2026 financial results and host a conference call on Thursday November 12, 2026. A passive stake exceeding 5% in the company, with voting power shared, is also reported. A Kalkine item references a 7.87% pre-market rise on October 29. Another headline references the price slipping 2.69% to $0.41 amid Ichimoku indicators. All items are marked as YELLOW light and MARKET WIRE impact. Per the Butterfly Supply-Chain Graph, no proprietary signals are present. Risk watch items include the sub-$1 share price and the market-data change of -8.4%.

Open Questions

What is the composition of the $3.1M FY 2025 revenue, and is it recurring?
What are the debt obligations, since the debt field is reported as N/A across periods?
What is the cash runway given $4.6M cash against FY 2025 FCF of $-5.7M?
Who holds the passive stake above 5%, and what is the voting arrangement?
What are the EPS and P/E values, which are not reported in the source data?

DYAI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Dyadic International Inc. (DYAI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to DYAI Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 15h ago

Dyadic International, Inc. Estimates – NASDAQ:DYAI

TradingView report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 18h ago

Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026

Yahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 21h ago

A passive stake tops 5% at Dyadic International (DYAI), with voting power shared.

Stock Titan report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Kalkine • 1d ago

What Explains the 7.87% Pre-Market Rise in Dyadic International (NASDAQ:DYAI) on October 29?

Kalkine report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

How One Biotech Stock Is Trying To Reduce A Big Hidden Cost

Yahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Dyadic International (DYAI) Slips 2.69% to $0.41 as Shares Sit Between Key Levels - Ichimoku Kumo Twist

https://www.siam.in/ report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Nasdaq sets two tests for Dyadic International stock

ad-hoc-news.de report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

DYAI Bull vs. Bear Conversation Board — What's Your Call at $0.38?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DYAI 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.32 (-11.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is DYAI (E • RQD 31/100) a Buy at $0.36?

Welcome to the DYAI (Dyadic International Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.30 (-16.7%)

Spot @ $0.36

Pump the brakes on DYAI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on DYAI, but look at what you are paying: current EV/EBITDA multiples with 24.9% gross margins. Unless Dyadic International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $0.45 (+25.0%)

Spot @ $0.36

DYAI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on DYAI, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.36 (52-wk range $0.34 - $1.60), any beat on forward guidance forces shorts and underweight funds to chase.